Secondary Analysis of RTOG 9704 Gemcitabine versus 5-FU in Resectable Pancreatic Cancer

Secondary Analysis of RTOG 9704 Gemcitabine versus 5-FU in Resectable Pancreatic Cancer

906 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Theodore S. Hong, MD of Massachusetts General Hospital discusses the Secondary Analysis of RTOG 9704 Gemcitabine versus 5-FU in Resectable Pancreatic Cancer at ASCO GI 2017
Up Next Autoplay